Compare NextEra Energy, Inc. (NEE) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NextEra Energy, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? NextEra Energy, Inc. trades at $83.01 (market cap $174.87B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: NextEra Energy, Inc. is the larger of the two by market cap, and NextEra Energy, Inc. pays a 2.97% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| NEE | VRTX | |
|---|---|---|
Market Cap | $174.87B | $134.06B |
Sector | Utilities | Health |
52-Week High | $97.88 | $557.96 |
52-Week Low | $69.83 | $376.62 |
Enterprise Value | $282.20B | $128.18B |
Dividend Yield | 2.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NextEra Energy (NEE) trades at $83.83, up 0.48% with a bearish technical signal despite strong analyst support. The company shows solid fundamentals with Q1 and Q2 2026 earnings beats, a 32.4% net income margin, and recent positive developments including a $1.9 billion DOE loan for nuclear plant restart. Cash flow improved to $1.6B net in 2025, though debt-to-asset ratio rose to 47.6%.
Outlook remains positive with 66.7% analyst buy ratings and a $100.20 consensus price target offering 19.5% upside. Key risks include rising leverage, competitive pressures, and execution of growth projects. The stock presents a growth opportunity in renewable energy with institutional backing, balanced by macroeconomic and regulatory uncertainties.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NextEra Energy, Inc.
NextEra Energy's regulated utility, Florida Power & Light, distributes power to more than 5 million customers in Florida. FP&L contributes more than 60% of the group's operating earnings. The renewable energy segment generates and sells power throughout the United States and Canada. Consolidated generation capacity totals more than 50 gigawatts and includes natural gas, nuclear, wind, and solar assets.
Read more on NEE →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
